03.01.16
Pharm-Olam International, a multi-national, full-service clinical research organization (CRO) to the biopharmaceutical and medical device industries, has been selected as the CRO for Infinity Pharmaceuticals for the conduct of Infinity’s Fresco study, a Phase II clinical trial of an investigational medicine for the treatment of relapsed/refractory follicular lymphoma.
“We are extremely pleased to continue our collaboration with Infinity,” said Sanjiv Suri, chief executive officer, Pharm-Olam. “The Infinity team required a fast, flexible solution to provide a timely quality deliverable. It is a credit to our project teams that Infinity has decided to continue with Pharm-Olam as a part of its future clinical plans.”
Infinity previously partnered with Pharm-Olam for clinical, project management, medical monitoring, data management, and regulatory services for Dynamo, a Phase II study for patients with refractory indolent non-Hodgkin’s lymphoma (iNHL).
“We are extremely pleased to continue our collaboration with Infinity,” said Sanjiv Suri, chief executive officer, Pharm-Olam. “The Infinity team required a fast, flexible solution to provide a timely quality deliverable. It is a credit to our project teams that Infinity has decided to continue with Pharm-Olam as a part of its future clinical plans.”
Infinity previously partnered with Pharm-Olam for clinical, project management, medical monitoring, data management, and regulatory services for Dynamo, a Phase II study for patients with refractory indolent non-Hodgkin’s lymphoma (iNHL).